TCIM
CRL icon

TIAA CREF Investment Management’s Charles River Laboratories CRL Stock Holding History

TIAA CREF Investment Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$45.1M Buy
310,779
+111,076
+56% +$14.6M 0.03% 430
2018
Q4 		$22.6M Buy
199,703
+5,841
+3% +$731K 0.02% 609
2018
Q3 		$26.1M Buy
193,862
+9,749
+5% +$1.2M 0.02% 633
2018
Q2 		$20.7M Buy
184,113
+3,593
+2% +$388K 0.01% 723
2018
Q1 		$19.3M Sell
180,520
-140,972
-44% -$15.2M 0.01% 778
2017
Q4 		$35.2M Sell
321,492
-44,099
-12% -$4.8M 0.02% 553
2017
Q3 		$39.5M Buy
365,591
+53,942
+17% +$5.54M 0.03% 516
2017
Q2 		$31.5M Sell
311,649
-60,714
-16% -$5.59M 0.02% 578
2017
Q1 		$33.5M Sell
372,363
-8,955
-2% -$761K 0.02% 561
2016
Q4 		$29.1M Buy
381,318
+134,301
+54% +$10.2M 0.02% 610
2016
Q3 		$20.6M Sell
247,017
-160,084
-39% -$13.4M 0.01% 762
2016
Q2 		$33.6M Buy
407,101
+94,180
+30% +$7.76M 0.03% 549
2016
Q1 		$23.8M Buy
312,921
+51,097
+20% +$3.78M 0.02% 682
2015
Q4 		$21M Buy
261,824
+39,173
+18% +$2.83M 0.02% 738
2015
Q3 		$14.1M Buy
222,651
+59,960
+37% +$4.31M 0.01% 868
2015
Q2 		$11.4M Sell
162,691
-82,547
-34% -$6.11M 0.01% 1059
2015
Q1 		$19.4M Buy
245,238
+96,144
+64% +$7.09M 0.01% 792
2014
Q4 		$9.49M Buy
149,094
+48,483
+48% +$3.04M 0.01% 1147
2014
Q3 		$6.01M Sell
100,611
-175,956
-64% -$10.1M ﹤0.01% 1474
2014
Q2 		$14.8M Sell
276,567
-44,520
-14% -$2.44M 0.01% 921
2014
Q1 		$19.4M Buy
321,087
+35,435
+12% +$2.07M 0.01% 808
2013
Q4 		$15.2M Buy
285,652
+82,451
+41% +$4.14M 0.01% 913
2013
Q3 		$9.4M Buy
203,201
+100,122
+97% +$4.59M 0.01% 1126
2013
Q2 		$4.23M Buy
+103,079
New +$4.42M ﹤0.01% 1647

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

TIAA CREF Investment Management's CRL Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Charles River Laboratories (CRL) stake by 56% in Q1 2019, buying an estimated $14.6M and bringing the position to 310,779 shares worth $45.1M. The position accounts for 0.03% of the portfolio, ranked #430.

TIAA CREF Investment Management first reported a position in CRL in Q2 2013 and has held it in 24 quarters since. 409 funds tracked by Wall St. Rank hold CRL as of Q1 2019.

  • TIAA CREF Investment Management held 310,779 shares of Charles River Laboratories worth $45.1M as of Q1 2019.
  • TIAA CREF Investment Management bought 111,076 Charles River Laboratories shares in Q1 2019, an estimated $14.6M.
  • Charles River Laboratories made up 0.03% of TIAA CREF Investment Management's portfolio in Q1 2019, its #430 holding.
  • TIAA CREF Investment Management first reported a position in Charles River Laboratories in Q2 2013 and has held it in 24 quarters since.
  • 409 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.